Review
doi: 10.1016/j.coi.2010.04.006.
Epub 2010 May 12.
Novel tuberculosis vaccines on the horizon
Affiliations
- PMID: 20471231
- DOI: 10.1016/j.coi.2010.04.006
Item in Clipboard
Review
Novel tuberculosis vaccines on the horizon
Curr Opin Immunol.
2010 Jun.
Abstract
Eleven new tuberculosis (TB) vaccines are in various phases of clinical trials. These include subunit vaccines to improve the current vaccine BCG, and recombinant BCG to substitute for BCG, both given pre-exposure to prevent active disease. A plethora of potential candidates have reached various stages of the pre-clinical development pipeline, some ready to enter Phase I clinical trial soon. A boost vaccine to top up the immunity of existing BCG is on the horizon and will have to suffice until a better candidate to replace BCG is ready. The live mutants of Mycobacterium tuberculosis show great promise, but face a myriad of regulatory challenges.
Copyright 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
[Novel vaccines against M. tuberculosis].Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
-
New tuberculosis vaccines.Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 1:57-62. doi: 10.1016/S0213-005X(11)70019-2. Enferm Infecc Microbiol Clin. 2011. PMID: 21420568 Review.
-
Antituberculous vaccine development: a perspective for the endemic world.Expert Rev Vaccines. 2009 Nov;8(11):1547-53. doi: 10.1586/erv.09.111. Expert Rev Vaccines. 2009. PMID: 19863247 Review.
-
Advances in tuberculosis vaccine strategies.Nat Rev Microbiol. 2006 Jun;4(6):469-76. doi: 10.1038/nrmicro1419. Nat Rev Microbiol. 2006. PMID: 16710326 Review.
-
Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.Vaccine. 2009 Oct 19;27(44):6179-85. doi: 10.1016/j.vaccine.2009.08.018. Epub 2009 Aug 25. Vaccine. 2009. PMID: 19712772
Cited by
-
Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis.EMBO Mol Med. 2011 Apr;3(4):222-34. doi: 10.1002/emmm.201000125. Epub 2011 Feb 16. EMBO Mol Med. 2011. PMID: 21328541 Free PMC article.
-
Production of a particulate hepatitis C vaccine candidate by an engineered Lactococcus lactis strain.Appl Environ Microbiol. 2011 Dec;77(24):8516-22. doi: 10.1128/AEM.06420-11. Epub 2011 Oct 7. Appl Environ Microbiol. 2011. PMID: 21984246 Free PMC article.
-
Vaccines, reverse vaccinology, and bacterial pathogenesis.Cold Spring Harb Perspect Med. 2013 May 1;3(5):a012476. doi: 10.1101/cshperspect.a012476. Cold Spring Harb Perspect Med. 2013. PMID: 23637311 Free PMC article.
-
Lactoferrin Augmentation of the BCG Vaccine Leads to Increased Pulmonary Integrity.Tuberc Res Treat. 2011;2011:835410. doi: 10.1155/2011/835410. Epub 2011 Apr 28. Tuberc Res Treat. 2011. PMID: 22567270 Free PMC article.
-
Malaria infections do not compromise vaccine-induced immunity against tuberculosis in mice.PLoS One. 2011;6(12):e28164. doi: 10.1371/journal.pone.0028164. Epub 2011 Dec 19. PLoS One. 2011. PMID: 22205939 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
